Primary tumors of the lung: should we consider thermal ablation as a valid therapeutic option?

References

• Meza R, Meernik C, Jeon J, et al. Lung cancer incidence trends by gender, race and histology in the United States, 1973–2010. PLoS One. 2015;10:e0121323.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
   PubMed Web of Science ®Google Scholar
• Rami-Porta R, Ball D, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol. 2007;2:593–602.
   PubMed Web of Science ®Google Scholar
• Rami-Porta R, Tsuboi M. Sublobar resection for lung cancer. Eur Respir J. 2009;33:426–435.
   PubMed Web of Science ®Google Scholar
• Raz DJ, Zell JA, Ou SH, et al. Natural history of stage I non-small cell lung cancer: implications for early detection. Chest. 2007;132:193–199.
   PubMed Web of Science ®Google Scholar
• Jeppesen SS, Schytte T, Brink C, et al. A comparison of stereotactic body radiation therapy (SBRT) versus no treatment in medically inoperable patients with early-stage non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 2014;90:S642.
   Web of Science ®Google Scholar
• Qiao X, Tullgren O, Lax I, et al. The role of radiotherapy in treatment of stage I non-small cell lung cancer. Lung Cancer. 2003;41:1–11.
   PubMed Web of Science ®Google Scholar
• Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303:1070–1076.
   PubMed Web of Science ®Google Scholar
• Ambrogi MC, Fanucchi O, Cioni R, et al. Long-term results of radiofrequency ablation treatment of stage I non-small cell lung cancer: a prospective intention-to-treat study. J Thorac Oncol. 2011;6:2044–2051.
   PubMed Web of Science ®Google Scholar
• Beland MD, Wasser EJ, Mayo-Smith WW, et al. Primary non-small cell lung cancer: review of frequency, location, and time of recurrence after radiofrequency ablation. Radiology. 2010;254:301–307.
   PubMed Web of Science ®Google Scholar
• Palussiere J, Lagarde P, Aupérin A, et al. Percutaneous lung thermal ablation of non-surgical clinical N0 non-small cell lung cancer: results of eight years' experience in 87 patients from two centers. Cardiovasc Intervent Radiol. 2015;38:160–166.
   PubMed Web of Science ®Google Scholar
• Pennathur A, Luketich JD, Abbas G, et al. Radiofrequency ablation for the treatment of stage I non-small cell lung cancer in high-risk patients. J Thorac Cardiovasc Surg. 2007;134:857–864.
   PubMed Web of Science ®Google Scholar
• Simon CJ, Dupuy DE, DiPetrillo TA, et al. Pulmonary radiofrequency ablation: long-term safety and efficacy in 153 patients. Radiology. 2007;243:268–275.
   PubMed Web of Science ®Google Scholar
• Ricke J, Jurgens JH, Deschamps F, et al. Irreversible electroporation (IRE) fails to demonstrate efficacy in a prospective multicenter phase II trial on lung malignancies: the ALICE trial. Cardiovasc Intervent Radiol. 2015;38:401–408.
   PubMed Web of Science ®Google Scholar
• Hinshaw JL, Lubner MG, Ziemlewicz TJ, et al. Percutaneous tumor ablation tools: microwave, radiofrequency, or cryoablation – what should you use and why? Radiographics. 2014;34:1344–1362.
   PubMed Web of Science ®Google Scholar
• Hinshaw JL, Littrup PJ, Durick N, et al. Optimizing the protocol for pulmonary cryoablation: a comparison of a dual- and triple-freeze protocol. Cardiovasc Intervent Radiol. 2010;33:1180–1185.
   PubMed Web of Science ®Google Scholar
• Koizumi T, Tsushima K, Tanabe T, et al. Bronchoscopy-guided cooled radiofrequency ablation as a novel intervention therapy for peripheral lung cancer. Respiration. 2015;90:47–55.
   PubMed Web of Science ®Google Scholar
• Ambrogi MC, Fontanini G, Cioni R, et al. Biologic effects of radiofrequency thermal ablation on non-small cell lung cancer: results of a pilot study. J Thorac Cardiovasc Surg. 2006;131:1002–1006.
   PubMed Web of Science ®Google Scholar
• Gillams AR, Lees WR. Radiofrequency ablation of lung metastases: factors influencing success. Eur Radiol. 2008;18:672–677.
   PubMed Web of Science ®Google Scholar
• Dupuy DE, Fernando HC, Hillman S, et al. Radiofrequency ablation of stage IA non-small cell lung cancer in medically inoperable patients: results from the American College of Surgeons Oncology Group Z4033 (Alliance) trial. Cancer. 2015;121:3491–3498.
   PubMed Web of Science ®Google Scholar
• Palussière J, Chomy F, Savina M, et al. Radiofrequency ablation of stage IA non-small cell lung cancer in patients ineligible for surgery: results of a prospective multicenter phase II trial. J Cardiothorac Surg. 2018;13:91.
   PubMed Web of Science ®Google Scholar
• Crabtree T, Puri V, Timmerman R, et al. Treatment of stage I lung cancer in high-risk and inoperable patients: comparison of prospective clinical trials using stereotactic body radiotherapy (RTOG 0236), sublobar resection (ACOSOG Z4032), and radiofrequency ablation (ACOSOG Z4033). J Thorac Cardiovasc Surg. 2013;145:692–699.
   PubMed Web of Science ®Google Scholar
• Uhlig J, Ludwig JM, Goldberg SB, et al. Survival rates after thermal ablation versus stereotactic radiation therapy for stage 1 non-small cell lung cancer: a national cancer database study. Radiology. 2018;289:862–870.
   PubMed Web of Science ®Google Scholar
• Spencer KL, Kennedy MPT, Lummis KL, et al. Surgery or radiotherapy for stage I lung cancer? An intention to treat analysis. Eur Respir J. 2019;53:1801568.
   PubMed Web of Science ®Google Scholar
• IJsseldijk MA, Shoni M, Siegert C, et al. Survival after SBRT for clinically diagnosed or biopsy-proven early-stage non-small cell lung cancer: a systematic review and meta-analysis. J Thorac Oncol. 2019;14:583–595.
   PubMed Web of Science ®Google Scholar
• Moore W, Talati R, Bhattacharji P, et al. Five-year survival after cryoablation of stage I non-small cell lung cancer in medically inoperable patients. J Vasc Interv Radiol. 2015;26:312–319.
   PubMed Web of Science ®Google Scholar
• Inoue M, Nakatsuka S, Jinzaki M. Cryoablation of early-stage primary lung cancer. Biomed Res Int. 2014;2014:521691.
   PubMed Web of Science ®Google Scholar
• Yang X, Ye X, Zheng A, et al. Percutaneous microwave ablation of stage I medically inoperable non-small cell lung cancer: clinical evaluation of 47 cases. J Surg Oncol. 2014;110:758–763.
   PubMed Web of Science ®Google Scholar
• Nelson DB, Tam AL, Mitchell KG, et al. Local recurrence after microwave ablation of lung malignancies: a systematic review. Ann Thorac Surg. 2018;107:1876–1883.
   PubMed Web of Science ®Google Scholar
• Niibe Y, Hayakawa K. Oligometastases and oligo-recurrence: the new era of cancer therapy. Jpn J Clin Oncol. 2010;40:107–111.
   PubMed Web of Science ®Google Scholar
• Kodama H, Yamakado K, Takaki H, et al. Lung radiofrequency ablation for the treatment of unresectable recurrent non-small-cell lung cancer after surgical intervention. Cardiovasc Intervent Radiol. 2012;35:563–569.
   PubMed Web of Science ®Google Scholar
• Iguchi T, Hiraki T, Gobara H, et al. Percutaneous radiofrequency ablation of lung cancer presenting as ground-glass opacity. Cardiovasc Intervent Radiol. 2015;38:409–415.
   PubMed Web of Science ®Google Scholar
• Hess A, Palussiere J, Goyers JF, et al. Pulmonary radiofrequency ablation in patients with a single lung: feasibility, efficacy, and tolerance. Radiology. 2011;258:635–642.
   PubMed Web of Science ®Google Scholar
• De Ruysscher D, Wanders R, Hendriks LE, et al. Progression-free survival and overall survival beyond 5 years of NSCLC patients with synchronous oligometastases treated in a prospective phase II trial (NCT 01282450). J Thorac Oncol. 2018;13:1958–1961.
   PubMed Web of Science ®Google Scholar
• Fonck M, Perez JT, Catena V, et al. Pulmonary thermal ablation enables long chemotherapy-free survival in metastatic colorectal cancer patients. Cardiovasc Intervent Radiol. 2018;41:1727.
   PubMed Web of Science ®Google Scholar
• Lee H, Jin GY, Han YM, et al. Comparison of survival rate in primary non-small-cell lung cancer among elderly patients treated with radiofrequency ablation, surgery, or chemotherapy. Cardiovasc Intervent Radiol. 2012;35:343–350.
   PubMed Web of Science ®Google Scholar
• Li X, Zhao M, Wang J, et al. Percutaneous CT-guided radiofrequency ablation as supplemental therapy after systemic chemotherapy for selected advanced non-small cell lung cancers. AJR Am J Roentgenol. 2013;201:1362–1367.
   PubMed Web of Science ®Google Scholar
• Gu XY, Jiang Z, Fang W. Cryoablation combined with molecular target therapy improves the curative effect in patients with advanced non-small cell lung cancer. J Int Med Res. 2011;39:1736–1743.
   PubMed Web of Science ®Google Scholar
• Weickhardt AJ, Scheier B, Burke JM, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol. 2012;7:1807–1814.
   PubMed Web of Science ®Google Scholar
• Xu Q, Zhou F, Liu H, et al. Consolidative local ablative therapy improves the survival of patients with synchronous oligometastatic NSCLC harboring EGFR activating mutation treated with first-line EGFR-TKIs. J Thorac Oncol. 2018;13:1383–1392.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823–1833.
   PubMed Web of Science ®Google Scholar
• den Brok MH, Sutmuller RP, van der Voort R, et al. In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res. 2004;64:4024–4029.
   PubMed Web of Science ®Google Scholar
• Grieco CA, Simon CJ, Mayo-Smith WW, et al. Percutaneous image-guided thermal ablation and radiation therapy: outcomes of combined treatment for 41 patients with inoperable stage I/II non-small-cell lung cancer. J Vasc Interv Radiol. 2006;17:1117–1124.
   PubMed Web of Science ®Google Scholar
• Kashima M, Yamakado K, Takaki H, et al. Complications after 1000 lung radiofrequency ablation sessions in 420 patients: a single center's experiences. AJR Am J Roentgenol. 2011;197:W576–W580.
   PubMed Web of Science ®Google Scholar
• Inoue M, Nakatsuka S, Yashiro H, et al. Percutaneous cryoablation of lung tumors: feasibility and safety. J Vasc Interv Radiol. 2012;23:295–302.
   PubMed Web of Science ®Google Scholar
• Wang H, Littrup PJ, Duan Y, et al. Thoracic masses treated with percutaneous cryotherapy: initial experience with more than 200 procedures. Radiology. 2005;235:289–298.
   PubMed Web of Science ®Google Scholar
• Mehta A, Oklu R, Sheth RA. Thermal ablative therapies and immune checkpoint modulation: can locoregional approaches effect a systemic response? Gastroenterol Res Pract. 2016;2016:1.
   Web of Science ®Google Scholar
• Katzman D, Wu S, Sterman DH. Immunological aspects of cryoablation of non-small cell lung cancer: a comprehensive review. J Thorac Oncol. 2018;13:624–635.
   PubMed Web of Science ®Google Scholar
• Schneider T, Hoffmann H, Dienemann H, et al. Immune response after radiofrequency ablation and surgical resection in nonsmall cell lung cancer. Semin Thorac Cardiovasc Surg. 2016;28:585–592.
   PubMed Web of Science ®Google Scholar